Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

New easy-to-use risk calculator helps predict heart failure patients' chances of survival

A UCLA team has developed an easy-to-use "risk calculator" that helps predict heart failure patients' chances of survival for up to five years and assists doctors in determining whether more or less aggressive treatment is appropriate.

23 Jan 2014

Adverse events for patients treated for heart attack and heart failure have declined, study finds

Adverse events for patients being treated for heart attack and heart failure have declined, according to a new study published in the January 23 issue of the New England Journal of Medicine. However, the analysis funded by the Agency for Healthcare Research and Quality found that there has not been a significant decrease in adverse events for patients being treated for pneumonia and those who are recovering from surgery.

22 Jan 2014

Sitting for long hours increases heart failure risk in men

Sitting for long periods increases heart failure risk in men, even for those who exercise regularly, according to new research published in the American Heart Association journal Circulation: Heart Failure.

21 Jan 2014

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

Novo Nordisk, a world leader in diabetes care, today announced the launch of the insulin delivery device NovoPen Echo in the United States. This is the first and only pen device available in the U.S. with half-unit dosing and a memory function that records the dose and time passed since the last injection.

From Novo Nordisk 21 Jan 2014

Clinical rule stratifies CAP patients’ cardiac risk

Researchers have generated and validated a clinical rule that accurately stratifies patients hospitalized for community acquired pneumonia according to their risk for cardiac complications.

20 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

FDA approves New Drug Application for PENNSA 2%

Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s).

17 Jan 2014

Immune system plays important role in heart's response to injury

The immune system plays an important role in the heart's response to injury. But until recently, confusing data made it difficult to distinguish the immune factors that encourage the heart to heal following a heart attack, for example, from those that lead to further damage.

16 Jan 2014

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.

15 Jan 2014

MRI method to map creatine in heart may help detect disorders earlier than traditional methods

A new MRI method to map creatine at higher resolutions in the heart may help clinicians and scientists find abnormalities and disorders earlier than traditional diagnostic methods, researchers at the Perelman School of Medicine at the University of Pennsylvania suggest in a new study published online today in Nature Medicine.

13 Jan 2014

Obesity interferes with blood pressure control

Patients who are overweight or obese have a high risk for uncontrolled blood pressure, despite often taking multiple antihypertensive agents, say researchers.

13 Jan 2014

Sutter Davis Hospital receives Malcolm Baldrige National Quality Award for excellent performance

Sutter Davis Hospital (SDH) has become the first organization in the greater Sacramento area and the smallest hospital ever to receive the Malcolm Baldrige National Quality Award, the nation's only Presidential honor that recognizes performance excellence in education, healthcare and business organizations.

10 Jan 2014

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure.

9 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Hospitals with higher rates of readmissions may suffer cut in Medicare payments by 2015

Hospitals that treat more poor seniors who are on both Medicaid and Medicare tend to have higher rates of readmissions, triggering costly penalties from the Centers for Medicare and Medicaid Services, finds a new study in Health Services Research.

8 Jan 2014

Research opens door to new direction of PAH treatment

The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology.

8 Jan 2014

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

CVRx, Inc., a privately held medical device company, today announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for patients with drug resistant hypertension.

7 Jan 2014

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for its drug candidate, Erdosteine, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.

7 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

Oxygen Biotherapeutics, Inc. ("OBI") a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on ClinicalTrials.gov, "Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass."

7 Jan 2014

Heart Failure News and Research

Further Reading

New easy-to-use risk calculator helps predict heart failure patients' chances of survival

Adverse events for patients treated for heart attack and heart failure have declined, study finds

Sitting for long hours increases heart failure risk in men

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

Clinical rule stratifies CAP patients’ cardiac risk

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

FDA approves New Drug Application for PENNSA 2%

Immune system plays important role in heart's response to injury

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

MRI method to map creatine in heart may help detect disorders earlier than traditional methods

Obesity interferes with blood pressure control

Sutter Davis Hospital receives Malcolm Baldrige National Quality Award for excellent performance

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Hospitals with higher rates of readmissions may suffer cut in Medicare payments by 2015

Research opens door to new direction of PAH treatment

Barostim Therapy: A cost-effective treatment for patients with drug resistant hypertension

FDA OOPD grants orphan drug designation to Alitair's Erdosteine for treatment of bronchiectasis

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News